Bridged Polycyclic Compounds for Antimicrobial Coatings
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendrimer synthesis methods are inefficient due to repeated and time-consuming purifications, defects in molecular structure, and encapsulation of other molecules, making them costly and difficult to scale up for commercial production, while existing dental materials fail to effectively prevent and treat oral diseases in both humans and animals.
Innovation Solution
Development of bridged polycyclic compounds with two or more cyclic groups, which can be used to couple pharmaceutically active agents, forming antimicrobial coatings and compositions that are easier and cheaper to synthesize, providing effective prevention and treatment of oral and otic maladies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendrimers are synthesized using traditional divergent or convergent methods, then the dendrimers can serve as carrier agents for pharmaceutical drugs, but the synthesis requires repeated and time-consuming purifications and suffers from defects in molecular structure
Solution Approach 1:
The invention segments the dendrimer synthesis into modular repeating units that can be pre-formed and then assembled. This allows for more efficient synthesis with fewer purification steps while maintaining molecular structure quality, directly addressing the time-consuming nature of traditional dendrimer synthesis methods
Solution Approach 2:
The invention performs preliminary formation of dendrimer building blocks and functional groups before final assembly. This preliminary action reduces the need for repeated purifications during synthesis, saving time while ensuring proper molecular structure formation
2Reliability
If dendrimers are synthesized using traditional methods, then they can attach pharmaceutical drugs to increase intracellular concentration, but the production becomes costly and difficult to scale up to commercial quantities
Solution Approach 1:
By segmenting the dendrimer into standardized modular units, the invention enables more efficient manufacturing and scaling. The modular approach allows for parallel synthesis and easier quality control, making commercial production more feasible while maintaining drug delivery effectiveness
Solution Approach 2:
The invention changes the synthesis parameters by using alternative chemistry that reduces purification requirements and improves yield. This enables scalable production at lower costs while maintaining the ability to effectively deliver drugs intracellularly
3Reliability
If traditional dental materials are used, then they provide basic dental care, but they fail to effectively prevent and treat oral diseases in middle-aged and elderly patients
Solution Approach 1:
The invention applies local quality by creating dental materials with specific functional groups tailored to different age groups and oral conditions. The bridged polycyclic compounds can be functionalized to provide targeted protection against periodontal disease, cavities, and other oral health issues specific to middle-aged and elderly patients
Solution Approach 2:
The invention uses composite materials combining bridged polycyclic compounds with dental materials. This creates a multi-functional system that provides both structural dental care and active disease prevention through the antimicrobial and anti-inflammatory properties of the bridged polycyclic compounds
4Reliability
If dendrimers are synthesized using conventional methods, then they can be used as carrier agents, but defects in molecular structure and encapsulation of other molecules occur
Solution Approach 1:
Segmenting the dendrimer into controlled modular units allows for precise assembly with fewer defects. The systematic approach to building the dendrimer structure reduces molecular structure inaccuracies while maintaining carrier agent functionality
Solution Approach 2:
The invention extracts and removes unwanted encapsulated molecules through improved purification methods that are less time-consuming. This takes out the harmful encapsulated substances while preserving the desired dendrimer structure and carrier functionality
Data Source
AI summary
A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents.